Hoth Therapeutics Advances Preclinical Development of HT-KIT With Altasciences Collaboration for Mast Cell-Derived Cancer Treatment

Hoth Therapeutics Advances Preclinical Development of HT-KIT With Altasciences Collaboration for Mast Cell-Derived Cancer Treatment Overview Company: Hoth Therapeutics, Inc. Indication: Mast Cell-Derived Cancers Drug: HT-KIT Trial Phase: Preclinical (N/A for IND-enabling studies) Nct ID: Not applicable Development Update Hoth Therapeutics, Inc., a patient-focused biopharmaceutical company, has a..

  • format_list_bulleted Pharmacology/BS
  • · 2024. 2. 27.
  • textsms

Hoth Therapeutics Announces IRB Approval for FDA Cleared First-In-Human Clinical Trial of HT-001 at Second Clinical Site

Hoth Therapeutics has received approval from the University of Texas MD Anderson Cancer Center Institutional Review Board (IRB) to proceed with its First-in-Human Phase 2a clinical trial of HT-001. This milestone marks multiple sites hosting the trial, as Washington University of St Louis previously approved it as well. The randomized, placebo-controlled, parallel Phase 2a dose-ranging study aim..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 15.
  • textsms